NK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonists
- 19 March 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (45)
- https://doi.org/10.1126/sciimmunol.aaz2738
Abstract
Several immunotherapy approaches that mobilize CD8(+) T cell responses stimulate tumor rejection, and some, such as checkpoint blockade, have been approved for several cancer indications and show impressive increases in patient survival. However, tumors may evade CD8(+) T cell recognition via loss of MHC molecules or because they contain few or no neoantigens. Therefore, approaches are needed to combat CD8(+ )T cell-resistant cancers. STING-activating cyclic dinucleotides (CDNs) are a new class of immune-stimulating agents that elicit impressive CD8(+) T cell-mediated tumor rejection in preclinical tumor models and are now being tested in clinical trials. Here, we demonstrate powerful CDN-induced, natural killer (NK) cell-mediated tumor rejection in numerous tumor models, independent of CD8(+) T cells. CDNs enhanced NK cell activation, cytotoxicity, and antitumor effects in part by inducing type I interferon (IFN). IFN acted in part directly on NK cells in vivo and in part indirectly via the induction of IL-15 and IL-15 receptors, which were important for CDN-induced NK activation and tumor control. After in vivo administration of CDNs, dendritic cells (DCs) up-regulated IL-15R alpha in an IFN-dependent manner. Mice lacking the type I IFN receptor specifically on DCs had reduced NK cell activation and tumor control. Therapeutics that activate NK cells, such as CDNs, checkpoint inhibitors, NK cell engagers, and cytokines, may represent nextgeneration approaches to cancer immunotherapy.Funding Information
- NIH Office of the Director (R01-AI113041)
- NIH Office of the Director (F31CA228381)
- Immunotherapy and Vaccine Research Initiative (IVRI) supported by Aduro Biotech (045535)
This publication has 65 references indexed in Scilit:
- The Innate Immune DNA Sensor cGAS Produces a Noncanonical Cyclic Dinucleotide that Activates Human STINGCell Reports, 2013
- Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptorProceedings of the National Academy of Sciences of the United States of America, 2011
- Type I interferon is selectively required by dendritic cells for immune rejection of tumorsThe Journal of Experimental Medicine, 2011
- Innate or Adaptive Immunity? The Example of Natural Killer CellsScience, 2011
- Role of Common-Gamma Chain Cytokines in NK Cell Development and Function: Perspectives for ImmunotherapyJournal of Biomedicine and Biotechnology, 2011
- STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunityNature, 2009
- Oncogenic stress sensed by the immune system: role of natural killer cell receptorsNature Reviews Immunology, 2009
- IL-15Rα chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentationThe Journal of Experimental Medicine, 2008
- Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15Immunity, 2007
- Natural killer cells, viruses and cancerNature Reviews Immunology, 2001